The ORIGIN 3 final efficacy data are strongly positive across all endpoints with a clean safety profile, supporting full approval. However, VERA has sold off -20% and -25% on prior positive readouts (see historical performance), suggesting the market may already price in approval. Watch for sBLA submission timing and any FDA advisory committee dynamics in 2027.
Price Chart
Executive Summary
Vera Therapeutics announced positive final efficacy results from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in IgA nephropathy, meeting all prespecified endpoints including eGFR preservation and reduced kidney disease progression. The company plans to submit a supplemental BLA in Q4 2026 for full FDA approval expected in 2027. This is a major catalyst for a commercial-stage biotech with a first-in-class approved product, though the stock has previously sold off on similar positive readouts.
Key Facts
- ORIGIN 3 met primary endpoint of statistically significant proteinuria reduction at 36 weeks
- TRUTAKNA achieved statistical significance in all prespecified endpoints including eGFR change from baseline and annualized slope
- TRUTAKNA significantly reduced risk of composite kidney disease progression events
- Favorable safety profile generally comparable to placebo; SAEs 7% vs 15% placebo; no deaths in TRUTAKNA group
- Plan to submit supplemental BLA to FDA in Q4 2026 for full approval expected in 2027
- Results published in New England Journal of Medicine and presented at ASN Kidney Week 2026
- TRUTAKNA is first and only FDA-approved BAFF and APRIL inhibitor for IgAN
Financial Impact
Full approval would expand label from accelerated approval (proteinuria reduction) to include kidney function preservation, potentially broadening the addressable IgAN patient population and supporting premium pricing. TRUTAKNA already has commercial revenue, and positive confirmatory data de-risks the franchise.
Risk Factors
- Full approval is not guaranteed; FDA may request additional data or impose label restrictions
- Competition from other IgAN therapies (e.g., Tarpeyo, Filspari) could limit market share
- Stock has historically sold off on positive clinical data, suggesting high expectations already priced in
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386581 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $29.05 | awaiting T+5 | — | $29.99 (+3.24%) |
Sep 15, 2026 6w ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $29.99 (−10.93%) |
Aug 10, 2026 11w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $29.99 (−0.99%) |
Aug 10, 2026 11w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $29.99 (−0.99%) |
Jul 9, 2026 15w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $29.99 (−29.35%) |
Jul 7, 2026 16w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $29.99 (−30.19%) |
Jun 11, 2026 19w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $29.99 (−10.88%) |
Jun 2, 2026 21w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $29.99 (−4.06%) |
Jun 2, 2026 21w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $29.99 (−4.06%) |
May 7, 2026 24w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $29.99 (−16.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers